drugset / Trial / NCT01482169
Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to demonstrate that intravenous regadenoson is equivalent to intravenous Adenoscan® for the physiological assessment of intermediate coronary lesions.
Timeline
- Start
- 2012-03
- Primary completion
- 2014-05
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adenosine | Small molecule | 140 ug/kg | Intravenous |
| Subject | Regadenoson | Diagnostic / imaging agent | 0.4 mg | Intravenous |